Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWTFO3)

• Drug Name: IMAZODAN Drug Info
• Synonyms: IMAZODAN HYDROCHLORIDE; Imazodan HCl; CI-914; UNII-5EP74J9Q34; Imazodan hydrochloride [USAN]; 89198-09-4; 4,5-Dihydro-6-(p-imidazol-1-ylphenyl)-3(2H)-pyridazinone monohydrochloride; 5EP74J9Q34; 4,5-Dihydro-6-(4-(1H-imidazol-1-yl)phenyl)-3(2H)-pyridazinone hydrochloride; Imazodan hydrochloride (USAN); 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-(1H-imidazol-1-yl)phenyl)-, monohydrochloride; 3(2H)-Pyridazinone, 4,5-dihydro-6-(p-(1-imidazolyl)phenyl)-, monohydrochloride; ACMC-20livl; AC1Q3ES0; C13H12N4O.HCl; SCHEMBL124243; AC1L1K29
• Cross-matching ID:
  PubChem CID: 55918
  CAS Number: CAS 84243-58-3
  TTD Drug ID: DMWTFO3

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 5A (PDE5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tadalafil	DMJZHT1	Benign prostatic hyperplasia	GA90	Approved	[3]
Udenafil	DM1IQRP	Erectile dysfunction	HA01.1	Approved	[4]
Vardenafil	DMTBGW8	Cystic fibrosis	CA25	Approved	[5]
Dipyridamole	DMXY30O	Atrial fibrillation	BC81.3	Approved	[6]
Papaverine	DMCA9QP	Brain ischaemia	8B1Z	Approved	[7]
Avanafil	DM75CXN	Erectile dysfunction	HA01.1	Approved	[8]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[9]
ICARIIN	DMOJQGT	N. A.	N. A.	Phase 3	[10]
EXISULIND	DMBY56U	Colorectal cancer	2B91.Z	Phase 3	[11]
PF-489791	DM3C8GQ	Chronic obstructive pulmonary disease	CA22	Phase 2	[12]

Drug(s) Targeting Phosphodiesterase 2A (PDE2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[13]
CP-461	DMEYMTX	Inflammatory bowel disease	DD72	Phase 2	[14]
ND7001	DMUBTC6	Mood disorder	6A60-6E23	Phase 1	[15]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1	DMC8935	N. A.	N. A.	Patented	[16]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2	DM4CSBD	N. A.	N. A.	Patented	[16]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2	DMS3ROL	N. A.	N. A.	Patented	[16]
Triazolo-pyridine derivative 5	DM1R205	N. A.	N. A.	Patented	[16]
PMID27321640-Compound-58	DM0NYK3	N. A.	N. A.	Patented	[16]
Triazolo-pyridine derivative 4	DM5ZQKS	N. A.	N. A.	Patented	[16]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3	DMZ61T8	N. A.	N. A.	Patented	[16]

Drug(s) Targeting Phosphodiesterase 3A (PDE3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[17]
Aminophylline	DML2NIB	Bronchial asthma	CA23	Approved	[18]
Anagrelide	DMSQ8MD	Thrombocythemia	3B63	Approved	[19]
Enoximone	DMQVZJD	Congestive heart failure	BD10	Approved	[20]
VESNARINONE	DMBKX3C	Cardiac failure	BD10-BD13	Approved	[21]
BEMORADAN	DMUL6GY	Heart failure	BD10-BD13	Phase 2	[8]
CI-930	DMADPQX	N. A.	N. A.	Discontinued in Phase 2	[22]
EMD-53998	DMVS8IE	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 1	[8]
LAS-31180	DMW2K1L	Heart failure	BD10-BD13	Terminated	[23]
BMY-20844	DMDPJ8M	N. A.	N. A.	Terminated	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 2A (PDE2A)	TTJGW1Z	PDE2A_HUMAN	Inhibitor	[1]
Phosphodiesterase 3A (PDE3A)	TT06AWU	PDE3A_HUMAN	Inhibitor	[2]
Phosphodiesterase 5A (PDE5A)	TTJ0IQB	PDE5A_HUMAN	Inhibitor	[1]

References

• [1] Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of conges... J Med Chem. 1984 Sep;27(9):1099-101.
• [2] 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
• [3] Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
• [4] Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
• [5] The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
• [6] Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
• [7] Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [9] cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
• [10] Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
• [11] Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
• [12] Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
• [13] The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
• [14] Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001 May;2(5):677-83.
• [15] Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures. Neurosignals. 2013;21(3-4):197-212.
• [16] Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
• [17] A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
• [18] Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
• [19] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
• [20] Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
• [21] Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
• [22] Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
• [23] Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
• [24] Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. J Med Chem. 1992 Jul 10;35(14):2688-96.